Purification and Characterization of Turtle Pepsinogen and Pepsin¹

Akira Hirasawa,* Senarath B.P. Athauda,* and Kenji Takahashi*¹ *-2

'Department of Biophysics and Biochemistry, Graduate School of Science, The University of Tokyo, Bunkyo-ku, Tokyo 113; and ^School of Life Science, Tokyo University of Pharmacy and Life Science, 1432-1 Horinouchi, Hachioji, Tokyo 192-03

Received for publication, April 19, 1996

Pepsinogen was purified from the gastric mucosa of soft-shelled turtle *(Trionyx sinensis)* **by a series of chromatographies on DEAE-cellulose, Sephadex G-100, and Q-Sepharose.** Upon chromatography on Q-Sepharose, it was separated into nine isoforms. These isoforms **showed a relative molecular mass of approximately 43,000 Da on sodium dodecyl sulfatepolyacrylamide gel electrophoresis, and isoforms 4 through 9 contained carbohydrate (approx. 2% each). Insofar as they were examined, their NH2-tenninal sequences differed only in showing substitution at a few positions. At pH 2.0, they were rapidly activated to the corresponding isoforms of pepsin in a stepwise manner. The nine isoforms showed** similar specific activity toward hemoglobin and hydrolyzed N-acetyl-L-phenylalanyl-**L-diiodotyrosine, a good substrate for pepsin A, at somewhat different rates. They were inhibited by pepstatin to various extents, more strongly than human pepsin C but less strongly than human pepsin A. All isoforms appeared to have similar cleavage specificity toward oxidized insulin B chain, which resembled those of both human pepsins A and C. A cDNA clone for one of the zymogen isoforms was isolated and sequenced. The amino acid sequence thus deduced was more homologous with those of mammalian pepsinogens A than those of mammalian pepsinogens C or prochymosin.**

Key words: amino acid sequence, cDNA sequence, pepsin, pepsinogen, turtle.

Pepsinogen, the precursor of the major gastric aspartic proteinase pepsin, is secreted from the gastric mucosa into the gastric lumen, where it is autocatalytically activated to pepsin under acidic conditions. It is classified into three major types: pepsinogen A, pepsinogen C (or progastricsin), and prochymosin (or neonatal pepsinogen) (1) . Further, pepsinogens, especially pepsinogens A, are often composed of several isoforms. To study the structure/ function relationship and molecular evolution of pepsinogens and pepsins, we have purified and characterized a number of pepsinogens from various sources, including human *(2-4),* monkey *(5-13),* bear *(14),* rabbit *(15),* guinea-pig *(16),* frog *(17),* and tuna *(18),* and sequenced several of them at the protein and/or DNA level. We have reported the complete amino acid sequences of human *(19),* monkey *(20),* and porcine *(21)* pepsinogens A, and human *(22),* monkey *(23),* rat *(24, 25),* guinea-pig (26), and frog *(17)* pepsinogens C. Other workers have reported the complete sequences for porcine *(26-29),* rabbit *(30),* and chicken (32) pepsinogens A, chicken embryonic pepsinogen *(32),* and bovine prochymosin *(33).* Thus, for non-mammalian species, the complete sequences of only three

Abbreviations: SDS, sodium dodecyl sulfate; PAGE, polyacrylamide gel electrophoresis.

pepsinogens have been determined. Furthermore, the biochemical properties of non-mammalian pepsins have been investigated only for chicken *(34),* frog *(17),* and tuna *(18).* To extend this series of studies, it is important to isolate more pepsinogens and pepsins from different sources, especially from non-mammalian species, and to elucidate their properties including amino acid sequences. So far, no studies have been reported on reptilian pepsinogens and pepsins.

In the present study, we have isolated multiple forms of pepsinogen from the gastric mucosa of soft-shelled turtle *(Trionyx sinensis)* as a representative of reptilian species and investigated their properties together with those of the corresponding pepsin isoforms. Further, a cDNA clone for a turtle pepsinogen isoform was isolated and sequenced.

EXPERIMENTAL PROCEDURES

*Materials—*The stomachs of soft-shelled turtles *(Torionyx sinensis)* were kindly supplied by Murakami Suppon and Hosendo, Tokyo. The following materials were obtained from the sources indicated. Bovine hemoglobin, Worthington Biochem.; DEAE-cellulose (DE-52), Whatman; Sephadex G-100 and Q-Sepharose, Pharmacia; reagents for amino acid analysis, Wako Pure Chem.; *N-ace*tyl-L-phenylalanyl-L-diiodotyrosine, NacalaiTesque; oxidized insulin B chain, Sigma; reagents for molecular cloning, Takara, Nippon gene, Toyobo, Boehringer-Mannheim, and/or BRL; DNA multiprime system and a reagent kit for separation of λ gt10 cDNA library, Amersham; a reagent kit for cDNA preparation, Boehringer-Mannheim; reverse

¹ This study was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan.

^{&#}x27; To whom correspondence should be addressed at: School of Life Science, Tokyo University of Pharmacy and Life Science, 1432-1 Horinouchi, Hachioji, Tokyo 192-03. Tel: +81-426-76-7146, Fax: + 81-426-76-7149, E-mail:kenjitak@ls.toyaku.ac.jp

transcriptase (MKV-RT), BRL; a DNA ligation kit, Takara; reagents for DNA sequencing, Applied Biosystems; radioactive compounds, Amersham and/or New England Nuclear.

Assay for Proteolytic Activity—Potential pepsin activity of pepsinogen and pepsin activity were determined essentially by the method of Anson *(35)* with slight modification. An enzyme solution (80 μ I) was mixed with 400 μ I of 2.5% acid-denatured hemoglobin in 0.1 M sodium formate buffer, pH 2.9, and incubated at 37'C for 30 min. To this was added 800 μ l of 5% (w/v) trichloroacetic acid and after standing for 30 min, the mixture was centrifuged at $10,000 \times q$ for 10 min. The absorbance at 280 nm of the supernatant was measured. One unit of activity was defined as the amount causing an increase in absorbance at 280 nm of 1.0 per min. Pepsin activity toward N -acetyl-L-phenylalanyl-L-diiodotyrosine was determined essentially by the method of Tang *(36).*

Determination of Protein—Protein concentration was determined by the method of Lowry *et al. (37)* with bovine serum albumin as a standard.

Purification of Pepsinogen—All purification procedures were performed at 4°C.

Step 1. Preparation of crude extract: The gastric mucosa (84 g) from four stomachs was homogenized with a Waring blender in 100 ml of 50 mM sodium phosphate buffer, pH 7.5. The homogenate was centrifuged at $3,000 \times q$ for 30 min. The supernatant was again centrifuged at $100,000 \times q$ for 120 min to yield a crude extract.

Step 2. DEAE-cellulose chromatography: The crude extract (110 ml) was applied to a column $(6 \times 22 \text{ cm})$ of DE-52 equilibrated with 50 mM sodium phosphate buffer, pH 7.5, and eluted with a gradient of NaCl (0 to 1 M) in a total volume of 2,000 ml of the same buffer at a flow rate of 120 ml/h. Fractions of 15.6 ml were collected.

Step 3. Sephadex G-100 chromatography: The active fractions from step 2 were combined, concentrated by ammonium sulfate precipitation, and dialyzed against 50 mM sodium phosphate buffer, pH 7.5. The dialyzed sample was applied to a column $(3.5 \times 150 \text{ cm})$ of Sephadex G-100 equilibrated with the same buffer. The protein was eluted at a flow rate of 18 ml/h and 6.3-ml fractions were collected.

Step 4. Q-Sepharose chromatography: The active fractions from step 3 were combined and one-fifteenth of the combined fraction was applied to a column of Q-Sepharose (HR 10/10, 10 ml) equilibrated with 50 mM piperazine HC1 buffer, pH 6.0. The protein was eluted with a gradient of NaCl (0 to 0.45 M) in a total volume of 1,000 ml of the same buffer at a flow rate of 30 ml/h. Fractions of 10 ml were collected. Major active fractions of each peak were pooled and each pooled fraction was purified further by rechromatography under the same conditions.

*Polyacrylamide Gel Electrophoresis (PAGE)—*SDS-PAGE was performed according to Laemmli *(38).* Protein was stained with Coomassie Brilliant Blue. Native PAGE and the subsequent activity staining were performed essentially as described by Furihata *et al. (39).*

Amino Acid Analysis—Each peptide sample was hydrolyzed in 0.3 ml of 6 N HC1 containing 0.05% phenol at 110'C for 24 h in an evacuated sealed tube and the amino acids were analyzed in a Hitachi 835 amino acid analyzer. Cysteic acid was determined after performic acid oxidation according to Moore *(40).*

Amino Acid Sequence Determination—The amino acid sequences of the $NH₂$ -terminal regions of pepsinogen and pepsin isoforms were determined by using an automated protein sequencer, model 477A, equipped with an on-line PTH-amino acid analyzer (model 120A) (Applied Biosystems).

Analysis of Carbohydrate—Carbohydrate in each pepsinogen isoform was analyzed by the phenol-sulfuric acid method of Dubois *et al. (41).*

Analysis of Phosphate—Phosphate bound to protein was determined according to Bartlett *(42).*

Activation of Pepsinogen to Pepsin—Each pepsinogen isoform solution was adjusted to pH 2.0 with 0.1 N HC1 and incubated at 14*C at a protein concentration of 0.13 mg/ml. Aliquots of $25 \mu l$ were removed at appropriate intervals, mixed with the SDS-PAGE buffer and submitted to SDS-PAGE. Protein was stained with Coomassie Brilliant Blue.

Hydrolysis of Oxidized Insulin B Chain—Oxidized bovine insulin B chain (100 μ g) was digested with onehundredth by weight of the enzyme in 10 mM Tris glycine buffer, pH 1.5, at 37'C for 3 h. The digest was analyzed by HPLC on a TSKgel ODS-120T column $(0.46 \times 25 \text{ cm})$ in a Hitachi 655A-11 HPLC system. Elution was performd with a gradient of acetonitrile (0 to 50% in 50 min) in 0.1% trifluoroacetic acid at a flow rate of 0.8 ml/min and monitored at 215 nm. Isolated peptide fractions were hydrolyzed and submitted to amino acid analysis as described above.

Isolation of a cDNA Clone and Nucleotide Sequence Analysis—Total RNA was obtained from the gastric mucosa essentially according to Chirgwin *et al. (43)* and submitted to oligo(dT)-cellulose chromatography. With the isolated $poly(A)^+$ RNA, cDNA was synthesized using a reverse transcriptase and a cDNA synthesis kit, and a λ gt10 cDNA library was constructed from this cDNA as described *(44).* The cDNA library was screened by the colony hybridization method of Grunstein *et al (45)* using ³²P-labeled human pepsinogen A cDNA as a probe. Hybridization was performed at 65'C overnight, and the filter was washed with $2 \times SSC$ and $0.2 \times SSC$. The isolated cDNA clone was digested with restriction endonucleases and the resulting fragments were inserted into pUC 118 and 119. Single-chain DNAs were isolated according to Kuchino and Takanami (46) and sequenced by Sanger's dideoxymediated chain-termination method *(47)* using an Applied Biosystems model 370A DNA sequencer.

RESULTS

Purification and Properties of Pepsinogen—Pepsinogen in the mucosal extract was purified as summarized in Table I. It was eluted as one major peak upon chromatographies on DEAE-cellulose and Sephadex G-100 (Fig. 1, a and b) and the Sephadex G-100 pooled fraction gave a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) corresponding to a molecular mass of approximately 43,000 Da (Fig. Id). Upon PAGE under non-denaturing conditions, however, both DEAE-cellulose and Sephadex G-100 fractions gave multiple bands of pepsinogen isoforms (data not shown). These isoforms could be separated reproducibly into nine fractions by chromatography on Q-Sepharose, as shown in Fig. lc. Each

fraction yielded an apparently single band of activity, and each showed different mobility from the others on PAGE under non-denaturing conditions (Fig. le), indicating that they were eluted from the Q-Sepharose column in the order of increasing net anionic charge. Pepsinogens 4 through 9 contained carbohydrate (approximately 2% each), whereas none of the nine isoforms contained phosphate. The amino acid compositions of the nine isoforms were similar to one another (data not shown).

*NH2-Terminal Amino Acid Sequences of Pepsinogen and Pepsin—*Isoforms 2, 5, 8, and 9, the major isoforms, were sequenced up to residue 30. Minor isoforms 6 and 7 were sequenced up to residues 30 and 18, respectively, and the other minor isoforms, 1, 3, and 4, up to residue 8. The sequences thus obtained were identical in all but three positions. The residue at position 8 was Lys in isoforms 1 through 7 and Gin in isoforms 8 and 9, and that at position 20 was His in isoforms 2,8, and 9 and Ala in isoforms 5 and 6. The residue at position 27 was indicated, although not conclusively, to be Lys in isoforms 2, 5, and 6 and Asn in isoforms 8 and 9. Thus, all or most of the isoforms are thought to have one of the following $NH₂$ -terminal sequences.

 $1 \t 5 \t 10 \t 15 \t 20 \t 25 \t 30$ LVTKVPLQ/KKGKSLRQNLKEH/AGLLE(D)F(K/N)KKH The major pepsin isoforms 2, 5, 8, and 9 were all sequenced up to residue 24 and the minor isoforms 6 and 7 up to residue 20. The results were identical, indicating that all or most of the pepsin isoforms have the same NH_2 -terminal sequence as shown below.

$1 \t 5 \t 10 \t 15 \t 20 \t 24$ ATEPLTNYMDAEYFGTISIGTPAQ

Activation of Pepsinogen—The pepsinogen isoforms were activated in a similar manner. The activation occurred very rapidly, taking only a few minutes for complete conversion of each pepsinogen isoform to the corresponding pepsin isoform. Figure 2 shows the time courses of activation of pepsinogen isoforms 7, 8, and 9 as typical examples. In each case, apparently two intermediate forms were

TABLE I. Purification of turtle pepsinogen.

Purification step	Total activity [*] (units)	Total protein (mg)	Specific activity (units/mg)	Activity vield (96)
Crude extract	3.129	1,623	1.9	100
DE-52	2,402	517	4.7	77
Sephadex G-100	1.273	206	6.2	41
Q-Sepharose ^b	660	57	$10.0 - 14.0$	21

•Potential pepsin activity was determined with hemoglobin as a substrate. 'One-fifteenth of the pooled Sephadex G-100 fraction was used; the sums of the activity, protein, and activity yields of the nine isoform fractions calculated for the total sample are shown.

Fig. 1. Purification of turtle pepsinogen. (a) DEAE-cellulose. The crude extract of turtle gastric mucosa (84 g) was applied to a column $(6 \times 22$ cm) of DE-52 equilibrated with 50 mM sodium phosphate buffer, pH 7.5. Fractions under the bar were pooled, (b) Sephadex G-100. The active fraction from DEAE-cellulose chromatography was concentrated and dialyzed against 50 mM sodium phosphate buffer, pH 7.5, and -31 K applied to a column (3.5×150) cm) of Sephadex G-100 equilibrated with the same buffer. Fractions under the bar were one-fifteenth of the enzyme fraction obtained by Sephadex G-100 chromatography was applied to a column of Q-Sepharose mM piperazine HC1 buffer, pH 6.0. (d) SDS/PAGE. The concentration of acrylamide was 10%. Lanes 1 and 6, marker proteins; lane 2, crude extract; lane 3, DE-52 pooled fraction; lane 4, Sephadex G-100 pooled fraction; lane 5, Sephadex G-100 pooled fraction incubated at pH2.0 and 37"C for 10 min, indicating conversion of pepseparated by Q-Sepharose chroproduced during the course of activation, indicating that the activation was a stepwise process, involving at least two intermediate forms.

Enzymatic Properties—The specific activity toward

Fig. 2. **Time course of activation of pepsinogen.** The results with isoforms 7, 8, and 9 are shown. They were incubated separately at pH 2.0 and 14*C at a protein concentration of 0.13 mg/ml. Aliquots were removed at appropriate intervals and submitted to SDS-PAGE. The proteins were stained with Coomassie Brilliant Blue. PG, pepsinogen; I, intermediate; P, pepsin.

hemoglobin was similar among the pepsin isoforms (Table I). Each isoform also hydrolyzed N -acetyl-L-phenylalanyl-

Fig. 3. **Pepstatin inhibition of turtle pepsin activity.** Each pepsinogen isoform (0.06 nmol) in 20 μ l of 10 mM piperazine HCl buffer, pH 6.0, was mixed with 20 μ l of pepstatin solution in aqueous dimethylsulfoxide and then $400 \mu l$ of acid-denatured hemoglobin solution was added to this mixture for assay under the standard conditions. The results with isoforms 1 (\Box), 4 (\blacksquare), 5 (\triangle), 6 (∇), 7 (\blacktriangle), and 9 (∇) are shown. Human pepsinogens A (\bullet) and C (\circ) were also used for comparison. The results with isoforms 2,3,7, and 8 (data not shown) were similar to those with isoforms 1, 4, 6, and 9, respectively.

 T T T T

 \mathbf{r}

Fig. **4. Analyses of the cleavage sites of oxidized insulin B chain by pepsin.** The results obtained with pepsin isoforms 1, 2, and 8 are shown, (a) HPLC patterns of 2-h digests of oxidized insulin B chain. An aliquot of each digest was applied to a TSKgel ODS-120T column (0.46×25 cm) and eluted with a gradient of acetonitrile (0-50% in 50 min) in 0.1% trifluoacetic acid at a flow rate of 0.8 ml/min.

Elution was monitored at 215 nm. (b) Sites of cleavage and yields of peptides. Large and small arrowheads indicate major and minor cleavage sites, respectively. The value above each arrowhead shows the estimated extent of cleavage (%). The cleavage sites by human pepsins A and C (49) are also shown for comparison.

 $Y - T$

L-diiodotyrosine, a good substrate for pepsin A, although the rate of hydrolysis varied among them; isoforms 1 and 2 had a specific activity somewhat lower than human pepsin A but much higher than that of human pepsin C, whereas isoforms 4 to 9 had a specific activity comparable to or somewhat higher than that of human pepsin A (data not

H P
cac cort Y N P S R K A K H **AOO** Y **TAT** F **TTC** P **CCC** ID **) 13 47 TCT AAO AAA TAC AAC** ceo **CCC CCT CAC** $\mathbf L$ $\mathbf T$ \overline{N} Y s
مەد $\mathbf T$ **yj 19 ACT OAD CCC CTO ACA AAC TAC ATO OAT O 14** L **TTO** G **OOA** D E **OAO TTT OAC** F E Y G T I S I G T P A Q **AOC** A D **OAT** S PL, **49 143 30 tt ACC ATC TCT**ATC **OOT**ACC
CCO
CCO
CAO

S
S
N
L
N
V
P

POP POD 140 CTD 700 CTD CCO **TTC** occ **OAO TAC** V **TTT** F **OOA** ET T G T **ACT** V **OTT OTT TTC OAC ACC** ooc V **OTO fll ltl OTO** $\tilde{\mathbf{e}}_{\mathbf{v}}^{\mathbf{c}}$ **TCT 4t TCO TCC AAO CTO TOO** Y $\begin{bmatrix} C \\ \hline \end{bmatrix}$ S $\begin{bmatrix} S \\ \hline \end{bmatrix}$ S $\begin{bmatrix} A \\ A \\ C \end{bmatrix}$ $\begin{bmatrix} C \\ \hline \end{bmatrix}$ **T** Q H N R F N P
ACA CAC CAC COC TTC AAO CCO s**TCO 77 131 ltl** N L D **OAO** S **TCC** T S T Y R A T S Q
TCC ACT TAC COO OCC ACC AOC CAO S_IQ
CATCCMO Y **TAT 13 197 140 AAO CTC TCX** I L G Y D N V Q M T G V **OTT** G G S **101 339 111** ooc **ACC** ooc **AOC ATO ACT 000 ATC CTO** ooc **TAC OAC AAC OTC CAO** F G L S E D T N Q I T **ACC** E **OAO** G G L V **113 313 3)1 CTT OTO OAC ACC AAC CAO ATC TTT** ooc **TTO** ooc ooc **AOT OAA** L D G \mathbf{L} G s F Y Y A P M I G T p **CCC** ooc **TCC ACC 141 431 CTO lit 314 TTT TAC TAC** occ **CCC ATO OAT** ooo **ATC CTO OOT** D N **A Y P S I A S S G A T P V occ acc** are are and **o** F **TTT OAC 117 47t AAC 141 431** M M **ATO** S **AOC** E **OAO** G ooo L **TTO** V **OTO** s**TCC** Q **OAO** D **OAC** L **CTC** F S **TTC TCC** V **OTO** Y **TAC** L **CTO 173 til 191 410** ATO AOC OAO 600 TTO TTO TTC CAR OAC CHE TTC TC C C N D
S
S
S
D
E Q S
N D
CAA
S
CORE AAT OAOC CAA
AOC GAA
AOC GAA
AOC GAA
AOC GAA
AOC GAA
AOC AA
CORE AA
TO AOC AA
CORE AA
TO AOC AA
GA **lit 97S 521** E **TAC TAO TCT GOO COO CTC CAT TOO ATO COO CTC COO CTC COO CTC COO CTC COO CTC COO CTC COO** T S **lot 113 OAO TCT If 0 ITI ACA** M **ACT** Y **TAC TOO OAA ATC AOO ATO OAC** s**AOC ATC ACT ATO AAT OOA** Q **CAO** W E I T D I T M N G T **ACC** T **111 171 201 • 24** I **ATC** A **OCT** [cl**TO*** S **TCC** G **OOT** G ooc **TOC** Q **CAO** A **OCT** I ATT I **ATT** D* **OAC** T ACT G ooc T **ACO** s
ग्ल **137 71* 222 172** L L A G P P S D V S N I N S Y I
 OTG CTO OCT 000 CCC CCC AGT GAC GTC TCC AAC ATG AAC TCC TAC ATG **193 717 231 T20** M
Ato S S N G E V S <mark>C</mark> S S
sc AAT soc aAs oTC AGC TOC AGC TCC s**AOO** L $rac{P}{\csc}$ G A
 α oc α cc A **Tl* 119 119** occ I **ATC** Y **ATO** P **CCT** S **TCC AOC** V **OTT** S **AOC CTO CCC** ooc E **OAA** A **AAT** F **TTC** I ooc N **TAAC OAO** I **ATC** D **OTC** N **AAC** S **AOC** V **OTT** I G ooc s**AOC** I **ATC** S AF
**oco TK
CD** S
TOT TOX F
S
TCC
TCC p **CCT** F **TTT** A occ E **QAO** S
مم **119 tf3 111** $S = S$ s**AOC 301 til 211 114** occ **TAC ATC ATA OAT TCA ATO** \overline{Q} **CC**L **N**I L
G
D
V
F I R
L Y

ATO
dAC
CAA
dod
cTC TOO ATC CTT GOC
dAC
CTC TAC **317 191 302 111** Y **TAC** V **OTT** V **OTC** F **TTT** D **OAC** R **COO** A **OCC** N **AAC** N **AAC** Q **CAO** V **OTO** G ooc L **CTO** A **OCT** S **TCC** L **CTO 333 1007 111 110** A **OCO TOA OCA COO TOC COT CCC TAO OAC ACT OCT OTO OAA CAO 000 TCC 31 + loot 1099 10i< TOA ATA ATC TTC ATT TCT CTA AAO TCC CAA CAA TOT OCA TAO AAC TAO 1103** 1104 TOO CTC CCG CCC CCA ATO TCC CAC ACA CCA TCT CTC CTA TAA TCT TOC 1151

Fig. 5. Sequencing of a turtle pepsinogen isoform cDNA and **the deduced amino acid sequence,** (a) Restriction map and sequencing strategy. The coding region is indicated by an open frame. The arrows indicate the directions and extents of sequence determination, (b) The nucleotide sequence (lower line) and the deduced amino acid sequence (in one-letter code) (upper line) are shown. The vertical arrow indicates the boundary between the propart and the pepsin moiety. The putative active site aspartic acid residues are shown with asterisks and the potential N -glycosylation sites with closed circles. The half-cystine residues are boxed.

shown). On the other hand, they were less sensitive to pepstatin than human pepsin A but more sensitive to pepstatin than human pepsin C as shown in Fig. 3. The HPLC patterns of the digests of oxidized insulin B chain were nearly identical among the isoforms except for isoforms 1 and 2. Therefore, most of the isoforms are thought to have essentially the same specificity. Figure 4 shows the HPLC pattern and the results of analysis of the peptides for isoform 8 together with those for isoforms 1 and 2, which gave slightly different HPLC patterns. Although these isoforms showed similar specificity, their relative extents of cleavage of the Phe²⁴-Phe²⁵ and Phe²⁵-Tyr²⁶ bonds varied significantly. These specificities, however, generally resembled those of both human pepsins A and C *(48)* as can be seen from Fig. 4.

Molecular Cloning of Pepsinogen cDNA and the Deduced Amino Acid Sequence—By screening 4,000 clones of the λ gt10 library using a human pepsinogen A cDNA as a probe, 22 positive clones were isolated. A restriction nuclease map of one of these clones is shown in Fig. 5a, and its determined nucleotide sequence and deduced amino acid sequence are shown in Fig. 5b. The cDNA clone encoded part (19 residues) of the propeptide and the complete amino acid sequence (315 residues) of the pepsin part of a pepsinogen isoform. The sequene starting from position 20 in the deduced sequence (Fig. 5b) agreed with the $NH₂$ terminal sequence of the pepsin isoforms determined at the protein level.

DISCUSSION

Multiple isoforms of pepsinogen have been found in various animal species. Notably, five pepsinogen A isoforms were found in human (3, *48)* and monkey (6), and six pepsinogen A isoforms in rabbit *(15)* stomachs. The nine isoforms in turtle stomach thus exceed these values. The same number of isoforms was also obtained from each stomach when three individual turtle stomachs were examined separately. Therefore, this multiplicity does not seem to be due to individual differences. Since these isoforms were separated from one another fairly well by Q-Sepharose chromatography and native PAGE, they should differ from each other in net charge. The fact that none of them contains phosphate suggests that such differences would be due primarily to amino acid substitutions. The $NH₂$ -terminal sequences of pepsinogen and pepsin isoforms so far determined do not account for the charge differences, so additional substitutions may be present elsewhere in the zymogen molecules. Further, isoforms 4 through 9 contain carbohydrate, which may also be partly responsible for generation of the isoforms. Carbohydrate-containing pepsinogens are rather rare. We previously reported occurrence of carbohydratecontaining pepsinogens A in Japanese monkey stomach as minor components (5) and carbohydrate-containing pepsinogen C in frog esophageal gland *(17).* In addition, only chicken pepsinogen A was reported to be a glycoprotein (32). It is also interesting to note that the turtle pepsinogen generally appeared to be activated much faster than pepsinogens from other sources (3, *17, 50).* The resulting pepsin was also fairly susceptible to autolysis (data not shown).

Some enzymatic properties of the pepsin isoforms were intermediate between those of human pepsins A and C.

lit ! CCA CAO TAA AAA AA

This seems to indicate that pepsin(ogen)s A and C may not always be clearly distinguishable by enzymatic properties alone. The results of $NH₂$ -terminal sequencing appear to indicate that all or most isoforms have the same $NH₂$. terminal sequence except for substitutions at a few positions. In mammalian pepsinogens A and C and prochymo- \sin , the NH₂-terminal sequences of the three groups are considerably different. Taken together, these findings suggest that all or most of the turtle pepsinogen isoforms belong to the same group of pepsinogen, and that the variations in several enzymatic properties among them are due to differences in sequence in the internal part of the pepsin moiety.

The NH₂-terminal Lys-His sequence deduced from the cDNA sequence overlaps the same sequence at position 29 to 30 in the $NH₂$ -terminal sequence of the major turtle pepsinogen isoforms determined at the protein level and this is supported by comparison with the known $NH₂$ terminal sequences of various pepsinogens. Therefore, we tentatively deduced a complete sequence of turtle pepsinogen by overlapping these sequences, as shown in Fig. 6, where this sequence is compared with the sequences of other typical pepsinogens. The sequences around the two active-site aspartic acid residues and the location of the three disulfide bonds are also conserved in turtle pepsinogen. All other pepsinogens so far sequenced have a conserved Lys-Tyr sequence near the carboxyl-terminal region of the propeptide; this Lys residue has been shown by X-ray crystallographic analysis to interact electrostatically with the active-site aspartyl residues in porcine

pepsinogen *{51-53)* and human progastricsin *(54)* and is assumed to be important for correct folding and stabilization of the pepsinogen molecule. Interestingly, this lysine residue is replaced with an Arg residue in turtle pepsinogen, indicating that the conserved Lys residue may be replaced with another basic residue, Arg. The identity of the deduced amino acid sequence of turtle pepsinogen was approximately 70, 69, and 63% with human *(19),* porcine *(21, 26-29),* and chicken *(31)* pepsinogens A, respectively, 59% with chicken embryonic pepsinogen *(32),* 55% with bovine prochymosin *(33),* and 50% with human pepsinogen C *(22).* Thus, the deduced sequence is thought to belong to A-type pepsinogens rather than C-type or prochymosintype pepsinogens. It is interesting to note that turtle pepsinogen shows somewhat higher homology with mammalian (porcine and human) pepsinogens A than with chicken pepsinogen A, indicating that the evolutionary distance is somewhat greater between turtle and chicken pepsinogens A than between turtle and mammalian pepsinogens A. On the other hand, in turtle pepsinogen, 5-residue deletions were observed at positions between 283 and 287 and between 330 and 331 (Fig. 6). A similar deletion in the first region was observed only with chicken pepsinogen A, and that in the second region was observed only with chicken embryonic pepsinogen and bovine prochymosin. The turtle pepsinogen sequence contains four potential N -glycosylation sites, whereas chicken embryonic pepsinogen contains five potential N -glycosylation sites, chicken pepsinogen A and bovine prochymosin have two, human pepsinogen C has one, and human and porcine

sinogen with those of some other typical pepsinogens. For turtle pepsinogen, the tentative amino acid sequence as described in the text is used. Amino acids are shown in one-letter code. The sequences are aligned so as to maximize the homology. The numbering is that of indicate deletions, and dashes indicate residues identical with those of turtle pepsinogen. Each vertical line indicates the boundary between turtle pepsinogen.

Fig. 6. Comparison of the amino acid sequence of turtle pep-
sinogen with those of some other typical pepsinogens. For turtle onic pepsinogen has not been determined. The positions of the active site aspartic acids are shown with asterisks and the potential N -glycosylation sites in each zymogen with closed circles. Dots pepsinogens A have none. Among these sites, two sites (Asn¹⁰² and Asn¹¹⁵) in chicken embryonic pepsinogen and one site (Asn¹⁰²) in human pepsinogen C are common to turtle pepsinogen, and two sites (Asn¹¹³ and Asn²¹⁸) are in the vicinity of Asn¹¹⁵ and Asn²¹⁵, respectively, of turtle pepsinogen. In these properties, turtle pepsinogen more closely resembles chicken pepsinogen A and/or chicken embryonic pepsinogen than mammalian pepsinogens A. Thus, turtle pepsinogen appears to retain certain structural features resembling those of chicken pepsinogen A and/or chicken embryonic pepsinogen, although it more closely resembles mammalian pepsinogens A in its amino acid sequence. These results are consistent with the phylogenic relationship of turtle, chicken, and mammals.

We are most grateful to Murakami Suppon Co., and Hosendo Co., Ltd., Tokyo for generous supply of the stomachs of soft-shelled turtles.

REFERENCES

- 1. Foltmann, B. (1981) Gastric proteinases—Structure, function, evolution and mechanism of action. *Essays Biochem.* **17,** 52-84
- 2. Kageyama, T. and Takahashi, K. (1980) Isolation of an activation intermediate and determination of the amino acid sequence of human pepsinogen A. *J. Biochem,* 88, 571-582
- 3. Athauda, S.B.P., Tanji, M., Kageyama, T., and Takahashi, K. (1989) A comparative study on the NH_2 -terminal amino acid sequences and some other properties of six isozymic forms of human pepsinogens and pepsins. *J. Biochem.* **106,** 920-927
- 4. Kageyama.T., Ichinose, M., Miki, K., Athauda, S.B.P., Tanji, M., and Takahashi, K. (1989) Difference of activation processes and structure of activation peptides in human pepsinogen A and progastricsin. *J. Biochem.* **105,** 12-15
- 5. Kageyama, T. and Takahashi, K. (1976) Pepsinogens and pepsins from gastric mucosa of Japanese monkey. Purification and characterization. *J. Biochem.* 79, 455-468
- 6. Kageyama, T. and Takahashi, K. (1976) Pepsinogen C and pepsin C from gastric mucosa of Japanese monkey. *J. Biochem.* 80, 983- 992
- 7. Kageyama, T. and Takahashi, K. (1977) The carbohydrate moiety of Japanese monkey pepsinogen—Its composition and site of attachment to protein. *Biochem. Biophys. Res. Commun.* **74,** 789-795
- 8. Kageyama, T. and Takahashi, K. (1978) Monkey pepsinogens and pepsins. III. Carbohydrate moiety of Japanese monkey pepsinogens and amino acid sequence around the site of its attachment to protein. *J. Biochem.* 84, 771-778
- 9. Kageyama, T. and Takahashi, K. (1980) Monkey pepsinogens and pepsins. IV. The amino acid sequence of the activation segment of Japanese monkey pepsinogen. *J. Biochem.* 88, 9-16
- 10. Kageyama, T. and Takahashi, K. (1980) Monkey pepsisnogens and pepsins. V. Purification, characterization, and amino acid sequence determination of crab-eating monkey pepsinogens and pepsins. *J. Biochem.* 88, 635-645
- 11. Kageyama, T. and Takahashi, K. (1982) Monkey pepsinogens and pepsins. VI. One-step activation of Japanese monkey pepsinogen to pepsin. *J. Biochem.* 92, 1179-1182
- 12. Kageyama, T. and Takahashi, K. (1985) Monkey pepsinogens and pepsins. VH. Analysis of the activation process and determination of the NH₂-terminal 60-residue sequence of Japanese monkey progastricsin, and molecular evolution of pepsinogens. *J. Biochem.* 97, 1235-1246
- 13. Kageyama, T. and Takahashi, K. (1987) Activation mechanism of monkey and porcine pepsinogens A. *Eur. J. Biochem.* **165,** 483-490
- 14. Kageyama, T. and Takahashi, K. (1983) Purification and characterization of pepsinogens and pepsins from Asiatic black bear, and amino acid sequence determination of the NH₂-terminal 60 residues of the major pepsinogen. *J. Biochem.* 94, 1557-1567
- 15. Kageyama, T. and Takahashi, K. (1984) Rabbit pepsinogens. Purification, characterization, analysis of the conversion process to pepsin, and determination of the NH,-terminal amino acid equences. *Eur. J. Biochem.* **141,** 261-269
- 16. Kageyama, T., Ichinose, M., Tsukada, S., Miki, K., Kurokawa, K., Koiwai, O., Tanji, M., Yakabe, E., Athauda, S.B.P., and Takahashi, K. (1992) Gastric procathepsin E and progastricsin from guinea pig. Purification, molecular cloning of cDNAs, and characterization of enzymatic properties, with special reference to procathepsin E. *J. Biol. Chem.* **267,** 16450-16459
- 17. Yakabe, E., Tanji, M., Ichinose, M., Goto, S., Miki, K., Kurokawa, K., Ito, H., Kageyama, T., and Takahashi, K.(1991) Purification, characterization, and amino acid sequences of pepsinogens and pepsins from the esophageal mucosa of Bullfrog *(Rana catesbeiana). J. Biol. Chem.* **266,** 22436-22443
- 18. Tanji, M., Kageyama, T., and Takahashi, K. (1988) Tuna pepsinogens and pepsins. Purification, characterization and amino-terminal sequences. *Eur. J. Biochem.* **177,** 251-259
- 19. Sogawa, K., Fujii-Kuriyama, Y., Mizukami, Y., Ichihara, Y., and Takahashi, K. (1983) Primary structure of human pepsinogen gene. *J. Biol. Chem.* 258, 5306-5311
- 20. Kageyama, T. and Takahashi, K. (1986) The complete amino acid sequence of monkey pepsinogen A. *J. Biol. Chem.* **261,** 4395- 4405
- 21. Tsukagoshi, N., Ando, Y., Tomita, Y., Uchida, R., Takemura, T., Sasaki, T., Yamagata, H., Udaka, S., Ichihara, Y., and Takahashi, K. (1988) Nucleotide sequence and expression in *Escherichia coli* of cDNA of swine pepsinogen: Involvement of the amino-terminal portion of the activation peptide segment in restoration of the functional protein. *Gene* **65,** 285-292
- 22. Hayano, T., Sogawa, K., Ichihara, Y., Fujii-Kuriyama, Y., and Takahashi, K. (1988) Primary structure of human pepsinogen C gene. *J. Biol. Chem.* **263,** 1382-1385
- 23. Kageyama, T. and Takahashi, K. (1986) The complete amino acid sequence of monkey progastricsin. *J. Biol. Chem.* **261,** 4406- 4419
- 24. Ichihara, Y., Sogawa, K., Morohaahi, K., Fujii-Kuriyama, Y., and Takahashi, K. (1986) Nucleotide sequence of a nearly full-length cDNA coding for pepsinogen of rat gastric mucosa. *Eur. J. Biochem.* **161,** 7-12
- 25. Ishihara, T., Ichihara, Y., Hayano, T., Katsura, I., Sogawa, K., Fujii-Kuriyama, Y., and Takahashi, K. (1989) Primary structure and transcriptional regulation of rat pepsinogen C gene. *J. Biol. Chem.* **264,** 10193-10199
- 26. Tang, J., Sepulveda, P., Marciniszyn, J., Jr., Chen, K.C.S., Huang, W.-Y., Tao, N., Liu, D., and Lanier, J.P. (1973) Amino-acid sequence of porcine pepsin. *Proc. Natl. Acad. Sci. USA* **70,** 3437-3439
- 27. Ong, E.B. and Perlmann, G.E. (1968) The amino-terminal sequence of porcine pepsinogen. *J. Biol. Chem.* **243,** 6104-6109
- 28. Pederson, V.B. and Foltmann, B. (1973) The amino acid sequence of a hitherto unobserved segment from porcine pepsinogen preceding the N-terminus of pepsin. *FEBS Lett.* **35,** 255-256
- 29. Stepanov, V.M., Baratova, L.A., Pugacheva, I.B., Belyanova, L.P., Revina, L.P., and Timokhina, E.A. (1973) N-terminal sequence of swine pepsinogen and pepsin. The site of pepsinogen activation. *Biochem. Biophys. Res. Commun.* **54,** 1164-1170
- 30. Kageyama, T., Tanabe, K., and Koiwai, O. (1990) Structure and development of rabbit pepsinogens. Stage-specific zymogens, nucleotide sequences of cDNAs, molecular evolution, and gene expression during development. *J. Biol. Chem,* **265,** 17031- 17038
- 31. Baudyš, M. and Kostka, V. (1983) Covalent structure of chicken pepsinogen. *Eur. J. Biochem.* **136,** 89-99
- 32. Hayashi, K., Agata, K., Mochii, M., Yasugi, S., Eguchi, G., and Mizuno, T. (1988) Molecular cloning and the nucleotide sequence of cDNA for embryonic chicken pepsinogen: Phylogenetic relationship with prochymosin. *J. Biochem.* **103,** 290-296
- 33. Foltmann, B., Pedereen, V.B., Jacobsen, H., Kauffman, D., and Wybrandt, G. (1977) The complete amino acid sequence of prochymosin. Proc. *Natl. Acad. Sci. USA* **74,** 2321-2324
- 34. Bohak, Z. (1969) Purification and characterization of chicken
- pepsinogen and chicken pepsin. *J. Biol. Chan.* **244,** 4638-4648 36. Anson, M.L. (1938) The estimation of pepsin, trypsin, papain, and cathepsin with hemoglobin. *J. Gen. Physiol.* **22,** 79-89
- 36. Tang, J. (1970) Gastricsin and pepsin. *Methods Enzymol.* **19,** 406-421
- 37. Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. (1951) Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* **193,** 265-275
- 38. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227,** 680-685
- 39. Furihata, C, Kawachi, T., and Sugimura, T. (1972) Premature induction of pepsinogen in developing rat gastric mucosa by hormones. *Biochem. Biophys. Res. Commun.* **47,** 705-711
- 40. Moore, S. (1963) On the determination of cystine as cysteic acid. *J. Biol. Chem.* **238,** 235-237
- 41. Dubois, M., Gilles, K.A., Hamilton, J.K., Rebers, P.A., and Smith, F. (1956) Colorimetric method for determination of sugars and related substances. *Anal. Chem.* 28, 350-356
- 42. Bartlett, G.R. (1959) Phosphorus assay in column chromatography. *J. Biol. Chem.* **234,** 466-468
- 43. Chirgwin, J.M., Przybyla, A.E., MacDonald, R.H., and Rutter, W.J. (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. *Biochemistry* **18,** 5294-5299
- 44. Huynh, T.V., Young, R.A., and Davies, R.W. (1985) Constructing and screening cDNA libraries in AgtlO and Agtll in *DNA Cloning* (Glover, D.M., ed.) Vol. 1, pp. 49-78, IRL Press, Oxford
- 45. Grunstein, M. and Hogness, D.S. (1975) Colony hybridization: A method for the isolation of cloned DNAs that contain a specific gene. *Proc. Nail. Acad. Sci. USA* **72,** 3961-3965
- 46. Kuchino, Y. and Takanami, M. (1984) Methods of M 13 shotgun DNA sequencing (in Japanese). *Protein, Nucleic Acid and*

Enzyme **29,** 294-306

- 47. Sanger, F., Nicklen, S., and Coulson, A.R. (1977) DNA sequencing with chain-terminating inhibitors. *Proc. Nad. Acad. Sci. USA* **74,** 5463-5467
- 48. Samloff, I.M. (1969) Slow moving protease and the seven pepsinogens. Electrophoretic demonstration of the existence of eight proteolytic fractions in human gastric mucosa. *Gastroenterology* 57, 659-669
- 49. Matsuzaki, O. and Takahashi, K. (1988) Improved purification of slow moving protease from human gastric mucosa and its action on the B chain of oxidized bovine insulin. *Biomed. Res.* 9, 515- 523
- 50. Takahashi, K. and Kageyama, T. (1985) Muliplicity and intermediates of the activation mechanism of zymogens of gastric aspartic proteinases in *Aspartic Proteinases and Their Inhibitors* (Kostka, V., ed.) pp. 265-282, Walter de Gruyter, Berlin & New York
- 51. James, M.N.G. and Sielecki, A.R. (1986) Molecular structure *of* an aspartic proteinase zymogen, porcine pepsinogen at 1.8 A resolution. *Nature* **319,** 33-38
- 52. Sielecki, A.R., Fujinaga, M., Read, R.J., and James, M.N.G. (1991) Refined structure of porcine pepsinogen at 1.8 A resolution. *J. Mol. Biol.* **219,** 671-692
- 53. Hartsuck, J.A., Koelsh, G., and Remington, S.J. (1992) The high resolution crystal structure of porcine pepsinogen. *Proteins* **13,**1- 95
- 54. Moore, S.A., Sielecki, A.R., Chernaia, M.M., Tarasova, N.I., and James, M.N.G. (1995) Crystal and molecular structures of human progastricsin at 1.62 A resolution. *J. Mol. Biol.* **247,** 466- 485